Wednesday, April 21, 2021
FORT COLLINS — Cytocom Inc. introduced Stephen Wilson joined the corporate efficient April 19 as head of worldwide improvements.
Wilson arrives at Cytocom after almost 25 years on the La Jolla Institute for Immunology, the place he was lively in biomedical analysis and served as chief working officer of the analysis facility.
As head of worldwide innovation at Cytomcom, Wilson will assist establish new indications for Cytocom’s current pipeline of brokers designed to rebalance the physique’s immune system and restore homeostasis. AIMS (Advanced Immunomodulating Multi-Receptor System) platform for drug discovery and improvement.
These analysis and improvement efforts will give attention to utilizing immune modulation to handle autoimmune and inflammatory situations, infectious illnesses, age-related pathologies and most cancers.
“Adding an govt of Steve’s caliber and expertise speaks volumes about Cytocom’s potential and our objective to grow to be a acknowledged chief in immune-modulating therapies that handle illness and autoimmune problems by rebalancing the physique’s immune system and restore homeostasis,” stated Mike HandleyPresident and CEO of Cytocom.
“Steve joins Cytocom at an thrilling time for the corporate as we work to advance a variety of late-stage medical belongings and full our proposed merger with Cleveland BioLabs and acquisition of ImQuest Life Sciences.
“With his expertise in research and development and business development, we look forward to maximizing the potential of our AIMS drug discovery and developing technology and entering into external research collaborations to further build our internal pipeline.”
Wilson earned a Ph.D. in Immunology from the University of Arizona’s College of Medicine and accomplished a postdoctoral fellowship at LJII.
During his almost 25 years with LJII, Wilson has held positions of accelerating accountability, most lately as govt VP and COO. In that position, he oversaw facility operations, labored to determine analysis collaborations between LJII and the biomedical trade, and performed a pivotal position within the Institute’s evolution right into a world-renowned biomedical analysis facility.
During his tenure, LJII grew from roughly $14 million in annual operations to greater than $80 million in annual analysis and improvement. Founded in 1988, LJII’s analysis actions have exceeded $1 billion so far.
Wilson can be a founding member of the board of administrators of Invivoscribe Technologies, Inc., a molecular diagnostics and oncology remedy firm.
“I believe Cytocom, with its breakthrough drug development technology and commitment to changing treatment paradigms, is poised for a transformative opportunity,” stated Wilson.
“As an immunologist, I have built a career in biomedical research, including identifying collaboration opportunities between industry and academia, and I believe Cytocom’s AIMS platform has the potential to deliver a new generation of immunotherapies that target the immune system. modulate and restore homeostasis.
“I look ahead to working with the Cytocom workforce to discover new indications for its current medical and improvement stage belongings and to domesticate exterior collaborations that might allow Cytocom to broaden the scope of its analysis and improvement efforts. broaden.”